Promise Ubanatu

Promise Bio is a precision medicine company dedicated to improving the management of chronic inflammatory diseases, starting with inflammatory bowel disease (IBD). The company utilizes a proprietary proteomics platform and machine learning to develop blood-based tests that monitor disease activity and predict treatment response. By providing objective, molecular-level insights, Promise Bio aims to replace invasive procedures like endoscopies and help clinicians optimize therapeutic choices for patients. Their technology focuses on identifying specific protein signatures in the blood to provide a comprehensive view of a patient's inflammatory state. The company was founded by Stanford-trained researchers and was part of the Y Combinator Winter 2021 cohort.